NYSE:ZYME
Zymeworks Inc Stock News
$9.06
-0.140 (-1.52%)
At Close: May 06, 2024
HC Wainwright Sees 'Multiple Catalyst Opportunities' After Atreca Inks Licensing Pact With Zymeworks
01:26pm, Wednesday, 06'th Apr 2022 Benzinga
Atreca Inc (NASDAQ: BCEL) announced a licensing agreement with Zymeworks Inc (NYSE: ZYME) to utilize their ZymeLink technology to develop novel antibody-drug conjugates (ADCs).
The agreement incl
Zymeworks Announces Participation in Upcoming Investor Conferences
08:30am, Friday, 01'st Apr 2022
VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announ
Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022
03:16pm, Tuesday, 15'th Mar 2022 Benzinga
Upgrades
For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the fourth quarter, compared
Zymeworks Inc. 2021 Q4 - Results - Earnings Call Presentation
04:05am, Friday, 25'th Feb 2022 Seeking AlphaZymeworks Inc. (ZYME) CEO Kenneth Galbraith on Q4 2021 Results - Earnings Call Transcript
04:03am, Friday, 25'th Feb 2022 Seeking AlphaZymeworks Inc. (ZYME) Reports Q4 Loss, Tops Revenue Estimates
11:20pm, Thursday, 24'th Feb 2022 Zacks Investment Research
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 10.38% and 56.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Inc. (ZYME) CEO Kenneth Galbraith on Q4 2021 Results - Earnings Call Transcript
11:03pm, Thursday, 24'th Feb 2022
Zymeworks Inc. (ZYME) CEO Kenneth Galbraith on Q4 2021 Results - Earnings Call Transcript
Zymeworks Non-GAAP EPS of -$0.99 beats by $0.14, revenue of $19.87M beats by $9.02M
09:34pm, Thursday, 24'th Feb 2022 Seeking Alpha
Zymeworks press release (NYSE:ZYME): Q4 Non-GAAP EPS of -$0.99 beats by $0.14.Revenue of $19.87M (+26.7% Y/Y) beats by $9.02M.
Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results
09:15pm, Thursday, 24'th Feb 2022 Business Wire
VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today reported financial results for the year ended December 31, 2021 and provided a summary of recent business highlights. “Since assuming my new role a month ago, I am pleased with our progress to focus on our key strategic priorities and improve our operational performance in order to deliver exceptional re
Zymeworks Inc. (ZYME) Reports Q4 Loss, Tops Revenue Estimates
08:00pm, Thursday, 24'th Feb 2022
Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 10.38% and 56.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Zymeworks Q4 2021 Earnings Preview
10:35pm, Wednesday, 23'rd Feb 2022 Seeking Alpha
Zymeworks (NYSE:ZYME) is scheduled to announce Q4 earnings results on Thursday, February 24th, after market close.The consensus EPS Estimate is -$1.13 (-82.3% Y/Y) and the consensus…
Earnings Preview: Zymeworks Inc. (ZYME) Q4 Earnings Expected to Decline
08:02pm, Thursday, 17'th Feb 2022 Zacks Investment Research
Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Zymeworks Inc. (ZYME) Q4 Earnings Expected to Decline
04:11pm, Thursday, 17'th Feb 2022
Zymeworks Inc. (ZYME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Tops Revenue Estimates
10:25pm, Tuesday, 15'th Feb 2022 Zacks Investment Research
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -5.75% and 139.40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the st
Zymeworks to Host Fourth Quarter and Full Year 2021 Results Conference Call
09:15pm, Tuesday, 08'th Feb 2022 Business Wire
VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2021 financial results after market close on February 24th, 2022. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on February 24th, 2022 at 4:30 p.m. ET. Confe